Skip to main content

Inés de Torres Ramirez

Sóc Facultatiu Especialista del Servei d'Anatomia Patològica de l'Hospital des de l'any 1989 i Professora Titular amb plaça vinculada a temps complert al Departament de Ciències Morfològiques de la Universitat Autònoma de Barcelona des de l’any 1999. Actualment coordino les àrees de Patologia Quirúrgica i d’Autòpsies al nostre servei. Tinc especial dedicació a la Patologia Gastrointestinal i Patologia Urològica sent la patòloga referent del Servei en aquest darrer àmbit. He estat involucrada en diversos projectes de recerca com a investigadora principal i actualment participo com a col•laboradora en recerca traslacional uro-oncològica , formant part del Grup de Recerca Biomèdica en Urologia del VHIR.

Institutions of which they are part

Biomedical Research in Urology
Vall Hebron Institut de Recerca
Head of Unit
Pathological anatomy
Cross-departmental services

Inés de Torres Ramirez

Institutions of which they are part

Biomedical Research in Urology
Vall Hebron Institut de Recerca
Head of Unit
Pathological anatomy
Cross-departmental services

Sóc Facultatiu Especialista del Servei d'Anatomia Patològica de l'Hospital des de l'any 1989 i Professora Titular amb plaça vinculada a temps complert al Departament de Ciències Morfològiques de la Universitat Autònoma de Barcelona des de l’any 1999. Actualment coordino les àrees de Patologia Quirúrgica i d’Autòpsies al nostre servei. Tinc especial dedicació a la Patologia Gastrointestinal i Patologia Urològica sent la patòloga referent del Servei en aquest darrer àmbit. He estat involucrada en diversos projectes de recerca com a investigadora principal i actualment participo com a col•laboradora en recerca traslacional uro-oncològica , formant part del Grup de Recerca Biomèdica en Urologia del VHIR.

Vaig cursar l'especialitat d'Anatomia Patològica al Hospital Vall d’Hebron i posteriorment vaig obtenir una Beca FPI de la UAB durant 3 anys per fer la tesi doctoral . El meu primer lloc de treball va ser a l’ Hospital de Sant Joan de Deu . Vaig complimentar la meva formació amb estades formatives a la Clínica Puigvert de Barcelona en Patologia Urològica en 1990 i al Presbyterian University Hospital of Pittsburgh (USA) en patologia quirúrgica funcional del trasplantament hepàtic amb i pulmonar en 1992 amb una beca BAE. Soc referent nacional en Patologia Urològica i he contribuït en les Guies i Recomanacions del Llibre Blanc de la Societat Española d’Anatomia Patològica i d’Oncologia. A l’Hospital Vall d’Hebron soc metgessa des de 1989 i he format part de diverses Comissions de l’Hospital essent actualment membre actiu del Comitè de Mortalitat i del Comitè Ètic d’Investigació Clínica.del Campus Vall d’Hebron . La meva participació en projectes de recerca ha comportat la co-autoria de mes 100 publicacions científiques. Participo de forma activa en diverses Societats Científiques Internacionals (USCAP, ENETs, ESP) . En la meva trajectòria universitària i com a professora titular del Departament de Ciències Morfològiques imparteixo classes d’Anatomia Patológica als Graus de Medicina i Ciències Biomèdiques, he dirigit tesis doctorals i he exercit càrrecs de gestió a la UAB.

Research lines

Involvement of the human Hepatitis A Viral Receptor (hHAVcr-1) in renal cancer development and progression. Value as a diagnostic and prognostic biomarker in renal carcinomas

We have postulated that hHAVcr-1 might constitute an important biomarker for early detection of ccRCC and could also be used as a target for therapy of kidney carcinomas, since immunotoxins directed against the monkey homologue of hHAVcr-1 could kill kidney cells.


Specific aims are focused to: i) determine the diagnostic and prognostic potential of hHAVcr-1 expression in renal cell carcinomas, by correlating hHAVcr-1 levels in archive, fresh surgical and TMA tissues  with tumor anatomo-pathological characteristics and patients outcome and, ii) determine the function of hHAVcr-1, which remains elusive, in development and progression of kidney carcinomas, using ccRCC derived cell lines with silenced or overexpressed hHAVcr-1. Tumors overexpressing or defective in hHAVcr-1 will be compared with controls, in relation to their behavior and anatomo-pathological characteristics. Differences are being correlated with proteomic and gene expression profiles obtained on each case. Differential expression pathways and target molecules correlating with absence/presence of hHAVcr-1 shall be identified. New strategies for diagnosis, prognosis and treatment of ccRCC must be further developed.

(Programa de Recerca en Cancer Renal CIBBIM-IRHUVH. )


IP: Inés de Torres Ramirez

Validation of predictive biomarkers in tissue microarrays (TMAs) (Translational research in prostate cancer)

All the above strategies leading to the discovery of new biomarkers, are validated in specifically designed tissue microarrays using immuno-histochemistry in FFPE samples from radical prostatectomies.

IP: Inés de Torres Ramirez

PIA and HGPIN as premalignant lesions of prostate cancer (Clinical research)

The main objective of this line is to understand the clinical significance of PIA and/or HGPIN lesions present in prostate biopsy. Once these are diagnosed, the search of markers specific for each lesion is also an objective of this line.   

IP: Inés de Torres Ramirez

Genomic transcriptional profile analysis in proliferative inflammatory atrophy (PIA) as a possible precursor of human prostate cancer

To analyse transcriptional profiles of normal, PIA (proliferative inflammatory atrophy), PIN (prostatic intraepithelial neoplasia)  and tumoral prostate using microarrays of selected tumoral tissue of prostatectomy specimens, in order to characterize  gene expression modifications in prostate cancer versus PIN and PIA.

To analyse the biological response on tumoral / non-tumoral and co-culture them with monocytes in order to study transcriptional profile changes.

From all the data obtained, overexpressed / underexpressed genes are being identified and      validated. Stromal and inflammatory genes also will be explored for their potential use as early markers for prostatic cancer and their ability to identify PIA as a precursor lesion.

(Prostate Research Traslational Unit.)


IP: Inés de Torres Ramirez

Projects

MnkImmunOnco) - Overcoming therapy resistance and immune evasion with a novel MNK inhibibtor

IP: Santiago Ramon y Cajal Agüeras
Collaborators: Inés de Torres Ramirez, Jordi Temprana Salvador, Vicente Peg Camara, Stefan Hummer
Funding agency: Fundació Institut Bioenginyeria de Catalunya
Funding: 0.01
Reference: M6871
Duration: 02/01/2023 - 31/12/2024

Rercerca biomèdica en urologia

IP: Joan Morote Robles
Collaborators: Fernando Lozano Palacio, Inés de Torres Ramirez, Marta Barber Servera, Enric Trilla Herrera, Olga Méndez Fernández, Ana Celma Domènech, Mercè Cuadras Solé, Carlos Serrano Burgos, Albert Carrión Puig , Maria Eugenia Semidey Raven, Carles Xavier Raventós Busquets, David Ruiz Casajuana, Jacques Planas Morin, Richard Mast, Anna Santamaria Margalef
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00858
Duration: 01/01/2022 - 30/06/2025

Radiogenomics for the prediction of prostate cancer aggressiveness through artificial intelligence.

IP: Joan Morote Robles
Collaborators: Inés de Torres Ramirez, Marta Barber Servera, Ana Celma Domènech, Jacques Planas Morin, Richard Mast, Lucas Regis Plácido
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI20/01666
Duration: 01/01/2021 - 30/06/2025

Contribución diferencial del epitelio intestinal a la fisiopatología de la diarrea crónica en el síndrome del intestino irritable y la colitis microscópica. Perfil clínico-biológico para el diagnóstico diferencial.

IP: Maria Vicario Perez
Collaborators: Beatriz Lobo Alvarez, Merce Albert Bayo, Inés de Torres Ramirez, Ana Maria Gonzalez Castro, Marc Pigrau Pastor, Xavier Serra Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI19/01643
Duration: 01/01/2020 - 30/06/2024

Related news

A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.

One more year, we join the Movember movement to raise awareness of the need for research to improve men's health and, in particular, that of patients with prostate cancer.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

Related professionals

Estrella Caballero Requero

Estrella Caballero Requero

Microbiology
Read more
Ding , Yuxin

Ding , Yuxin

Predoctoral researcher
Biomedical Research in Melanoma
Read more
Maus , Mate

Maus , Mate

Senior researcher
Read more
Odile Romero Santo-Tomas

Odile Romero Santo-Tomas

Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.